NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Pyrrhonian,

That is a possibility if there is no real or only minimal benefit being seen from DCVax-L. If there is stronger benefit for PFS but OS separation is being delayed by crossover, then to do as you suggest and have no crossover would mean FDA is willing to knowingly kill people to make NWBO prove that it can demonstrate added OS benefit in this setting. Ethical dilema big time. They would find another way to get what they want without putting patients at risk especially if mesenchymal GBM is responding exceptionally well as Dr. Linda Liau mentioned and multiple studies have suggested.